Advertisement
Canada markets close in 5 hours 48 minutes

  • S&P/TSX

    22,387.44
    +128.28 (+0.58%)
     

  • S&P 500

    5,196.86
    +9.19 (+0.18%)
     

  • DOW

    39,180.58
    +124.19 (+0.32%)
     

  • CAD/USD

    0.7304
    +0.0016 (+0.22%)
     

  • CRUDE OIL

    79.49
    +0.50 (+0.63%)
     

  • Bitcoin CAD

    83,981.18
    -1,243.92 (-1.46%)
     

  • CMC Crypto 200

    1,318.39
    +18.30 (+1.41%)
     

  • GOLD FUTURES

    2,332.30
    +10.00 (+0.43%)
     

  • RUSSELL 2000

    2,054.85
    -0.29 (-0.01%)
     

  • 10-Yr Bond

    4.5000
    +0.0080 (+0.18%)
     

  • NASDAQ

    16,303.34
    +0.58 (+0.00%)
     

  • VOLATILITY

    13.23
    +0.23 (+1.77%)
     

  • FTSE

    8,381.12
    +27.07 (+0.32%)
     

  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     

  • CAD/EUR

    0.6778
    +0.0002 (+0.03%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS DOW EYES EXTENDING 6-DAY WIN STREAK

Airbnb shares slump as gloomy Q2 forecasts fan slowdown worries

Stocks in play: Resverlogix Corp.

Baystreet.ca
·1 min read

Announced recent published findings in the high-impact journal, Proceedings of the National Academy of Sciences (PNAS),that further supports other 2020 publications and provides new evidence for the therapeutic potential of BET inhibitors in the treatment of COVID-19. A publication titled: “Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2”, highlights the important role that host cell receptors play in enabling viral entry into cells, and presents direct evidence that BET inhibitors reduce SARS-CoV-2 (the scientific name for the virus responsible for COVID-19) infection by inhibiting the expression of these receptors. The publication also acknowledges Resverlogix and the Company’s plans to confirm the hypothesis with a clinical trial utilizing its advanced BET inhibition technology. Resverlogix Corp. shares T.RVX are trading up $0.07 at $1.08.

Read: